Evidence map›Paper›PMID 37814146›Full record

ArticleCerebellum (London, England)2024

Opsoclonus-Myoclonus-Ataxia Syndrome Due to Covid-19.

Michael Adamaszek, Soenke Langner, Jan Mehrholz, Alexander Heiinrich

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Cerebellum (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Michael AdamaszekDepartment of Neurological and Neurocognitive Rehabilitation, Klinik Bavaria Kreischa, An der Wolfsschlucht, 1-2 01731, Kreischa, Germany. michael.adamaszek@klinik-bavaria.de.
Soenke LangnerDepartment of Radiology, Rostock University Medical Center, Schillingallee 35, 18057, Rostock, Germany.
Jan MehrholzDepartment of Public Health, Dresden Medical School, Technical University Dresden, Dresden, Germany.
Alexander HeiinrichNeurology and Psychiatry Group Practice, Geislingen, Germany.
Klinik Bavaria · DETU Dresden · DEUniversity of Rostock · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Opsoclonus-myoclonus syndrome (OMS) as a rare neurological encephalopathic entity associated with non-specific infections or cancer processes has been repeatedly described in the setting of SARS-CoV-2 infection. We report a case of a 53-year-old man with SARS-CoV-2 infection, who developed clinical features of opsoclonus-myoclonus ataxia syndrome including cognitive impairments with a prolonged course of disease. Of particular note, cerebrospinal fluid (CSF) analysis revealed the production of myelin oligodendrocyte glycoprotein (MOG) antibodies, suggesting an underlying neuroimmunological mechanism associated with infection with the novel SARS-CoV-2 virus.

Indexed as

COVID-19Opsoclonus-Myoclonus SyndromeHumansMaleMiddle AgedMyelin-Oligodendrocyte GlycoproteinSARS-CoV-2Myelin-Oligodendrocyte GlycoproteinMyelin oligodendrocyte glycoproteinOpsoclonus myoclonus ataxia syndromeParainfectious diseaseSARS-CoV-2

Identifiers

PMID37814146
OpenAlexW4387445691

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.